Welcome to our dedicated page for APOLLOMICS SEC filings (Ticker: APLMW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apollomics Inc. filings document foreign issuer current reports, oncology program updates, financing transactions, governance changes, and liquidity-related disclosures. The company furnishes Form 6-K reports and references Form 20-F reporting status, with exhibits covering financial results, clinical updates for vebreltinib, and corporate developments affecting ongoing operations.
The filing record also covers material agreements, related-party convertible note financing, PIPE share issuance, resale registration obligations, board and committee appointments, proxy materials, and risk disclosures tied to cash resources, collaboration payments, Nasdaq listing compliance, and the company’s capital structure as a Cayman Islands issuer with Class A ordinary shares and warrants.
Apollomics Inc. reported that, due to its cash position, it is terminating all U.S. employees, including its Chief Executive Officer, Dr. Guo-Liang Yu, and Chief Financial Officer, Dr. Matthew Plunkett, effective August 29, 2025. This indicates a severe reduction of U.S. operations and leadership.
The company also stated that it expects to discontinue all activities related to its SPARTA clinical trial as soon as possible, signaling a shutdown of this development program. In addition, Apollomics has called an Extraordinary General Meeting of Shareholders for September 4, 2025, to seek shareholder approval for winding up the company, which would effectively bring its corporate existence to an end if approved.